Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects

Background  Recombinant (rec-) coagulation factor VIII concentrates available for hemophilia A (HA) treatment differ in cell line production and structure, which could affect their pharmacodynamics and immunogenicity. Clinical trials showed that previously untreated patients with severe HA present h...

Descripción completa

Detalles Bibliográficos
Autores principales: De Cristofaro, Raimondo, Sacco, Monica, Lancellotti, Stefano, Berruti, Federico, Garagiola, Isabella, Valsecchi, Carla, Basso, Maria, Di Stasio, Enrico, Peyvandi, Flora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524925/
https://www.ncbi.nlm.nih.gov/pubmed/31249992
http://dx.doi.org/10.1055/s-0039-1688413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524925/
https://www.ncbi.nlm.nih.gov/pubmed/31249992
http://dx.doi.org/10.1055/s-0039-1688413

Ejemplares similares